Cardiol Therapeutics (CRDL)

$1.02 -0.03 (-2.86%)
Market Cap 117.33M
Revenue (ttm) 0.00
Net Income (ttm) -26.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 268,800
Avg Vol 345,614
Day's Range N/A - N/A
Shares Out 111.74M
Stochastic %K 40%
Beta 1.02
Analysts Strong Sell
Price Target $6.74

Company Profile

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutan...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 289 910 0850
Fax: 905 481 2394
Address:
2265 Upper Middle Road East, Suite 602, Oakville, Canada
Covode13
Covode13 Mar. 12 at 12:49 PM
$CRDL
0 · Reply
TheWinningStock
TheWinningStock Mar. 11 at 9:41 PM
$CRDL ....🤑
1 · Reply
ElieoG
ElieoG Mar. 11 at 2:28 PM
$CRDL good volume allready and breaking some 3 months resistance, possible breakout?
1 · Reply
VixTyler
VixTyler Mar. 11 at 5:59 AM
$CRDL Completion of enrollment is expected by the end of Q2 2026, setting the stage for a top-line data readout in the second half of 2026.
0 · Reply
zeke1019
zeke1019 Mar. 10 at 3:30 PM
$CRDL insiders are buying... Cardiol Therapeutics (CRDL) has experienced significant, consistent insider buying, primarily in late 2024 and October 2025, with no recorded sales in the last 3 years. Key executives, including CEO David Elsley and CFO Christopher Waddick, bought shares, signaling confidence following positive Phase 2 trial results.
1 · Reply
Covode13
Covode13 Mar. 10 at 12:08 PM
$CRDL
0 · Reply
Fastcapital
Fastcapital Mar. 9 at 5:06 PM
$CRDL https://finance.yahoo.com/news/cardiol-therapeutics-touts-phase-iii-230226821.html
0 · Reply
zeke1019
zeke1019 Mar. 9 at 1:55 PM
$CRDL Steve Grasso /cnbc backing!
5 · Reply
Covode13
Covode13 Mar. 6 at 7:29 PM
$CRDL
0 · Reply
NancyPelosi____insider
NancyPelosi____insider Mar. 6 at 6:08 PM
$CRDL absolute dogshit
1 · Reply
Latest News on CRDL
Cardiol Therapeutics Inc at TD Cowen Healthcare Conference Transcript

2026-03-04T21:00:29.000Z - 9 days ago

Cardiol Therapeutics Inc at TD Cowen Healthcare Conference Transcript

Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference

Wed, 25 Feb 2026 07:27:00 -0500 - 16 days ago

Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference

Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure

Tue, 10 Feb 2026 07:27:00 -0500 - 4 weeks ago

Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure

Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million

Fri, 23 Jan 2026 09:16:00 -0500 - 7 weeks ago

Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million

Cardiol Therapeutics announces $13.5M bought-deal private placement

2026-01-16T13:57:00.000Z - 2 months ago

Cardiol Therapeutics announces $13.5M bought-deal private placement

Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million

Fri, 16 Jan 2026 08:46:00 -0500 - 2 months ago

Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million

Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million

Fri, 16 Jan 2026 08:42:00 -0500 - 2 months ago

Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million

Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

Tue, 13 Jan 2026 07:27:00 -0500 - 2 months ago

Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research... • news

2025-12-17T13:38:24.000Z - 3 months ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research... • news

Cardiol Therapeutics Inc To Present Phase II ARCHER Results Transcript

2025-12-02T21:22:00.000Z - 3 months ago

Cardiol Therapeutics Inc To Present Phase II ARCHER Results Transcript

Cardiol Therapeutics (CRDL): HC Wainwright & Co. Reiterates Buy Rating | CRDL Stock News

2025-12-01T18:31:54.000Z - 3 months ago

Cardiol Therapeutics (CRDL): HC Wainwright & Co. Reiterates Buy Rating | CRDL Stock News

New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

Mon, 01 Dec 2025 07:27:00 -0500 - 3 months ago

New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040

Thu, 13 Nov 2025 07:45:00 -0500 - 4 months ago

Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040

Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases

Wed, 05 Nov 2025 07:45:00 -0500 - 4 months ago

Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases

Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027

Tue, 21 Oct 2025 07:27:00 -0400 - 5 months ago

Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027

Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027

Fri, 17 Oct 2025 16:34:00 -0400 - 5 months ago

Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027

Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference

Mon, 11 Aug 2025 07:27:00 -0400 - 7 months ago

Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference

Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis

Wed, 06 Aug 2025 07:27:00 -0400 - 7 months ago

Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis

Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis

Tue, 22 Jul 2025 07:27:00 -0400 - 8 months ago

Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis

Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders

Thu, 29 May 2025 07:27:00 -0400 - 10 months ago

Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders

Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDT

Tue, 27 May 2025 07:27:00 -0400 - 10 months ago

Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDT

Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors

Tue, 29 Apr 2025 07:27:00 -0400 - 11 months ago

Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors

Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

Wed, 16 Apr 2025 07:27:00 -0400 - 11 months ago

Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

Cardiol Therapeutics Announces Year-End 2024 Update on Operations

Tue, 01 Apr 2025 07:27:00 -0400 - 1 year ago

Cardiol Therapeutics Announces Year-End 2024 Update on Operations

Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Mon, 03 Mar 2025 07:27:00 -0500 - 1 year ago

Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure

Thu, 20 Feb 2025 07:27:00 -0500 - 1 year ago

Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure

Cardiol Therapeutics: Bargain Stock Price With Share Price Appreciation Catalysts

2025-02-19T05:13:10.000Z - 1 year ago

Cardiol Therapeutics: Bargain Stock Price With Share Price Appreciation Catalysts

Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Tue, 04 Feb 2025 07:27:00 -0500 - 1 year ago

Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis

Thu, 19 Dec 2024 08:30:00 -0500 - 1 year ago

PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis

CBD-Based Drug Reduces Pericarditis Pain And Inflammation, Shows New Clinical Study

2024-11-19T19:24:47.000Z - 1 year ago

CBD-Based Drug Reduces Pericarditis Pain And Inflammation, Shows New Clinical Study

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

Mon, 18 Nov 2024 11:37:00 -0500 - 1 year ago

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index

Wed, 13 Nov 2024 08:00:00 -0500 - 1 year ago

Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index

IRW-News: Cardiol Therapeutics Inc. : Cardiol Therapeutics will CardiolRx in eine Studie der späten Phase an Patienten mit rezidivierender Perikarditis überführen

2024-10-22T14:46:21.000Z - 1 year ago

IRW-News: Cardiol Therapeutics Inc. : Cardiol Therapeutics will CardiolRx in eine Studie der späten Phase an Patienten mit rezidivierender Perikarditis überführen

Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis

Tue, 22 Oct 2024 06:30:00 -0400 - 1 year ago

Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis

Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option

Fri, 11 Oct 2024 08:39:00 -0400 - 1 year ago

Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option

Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares

Thu, 10 Oct 2024 09:09:00 -0400 - 1 year ago

Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares

Why Cardiol Therapeutics (CRDL) Stock Is Down 20% Today

2024-10-09T14:41:56.000Z - 1 year ago

Why Cardiol Therapeutics (CRDL) Stock Is Down 20% Today

Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares

Wed, 09 Oct 2024 07:58:00 -0400 - 1 year ago

Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares

Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares

Tue, 08 Oct 2024 16:01:00 -0400 - 1 year ago

Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares

Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis

Tue, 24 Sep 2024 07:27:00 -0400 - 1 year ago

Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis

Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024

Tue, 10 Sep 2024 07:27:00 -0400 - 1 year ago

Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024

Cardiol Therapeutics: First-Mover In CBD-Based Treatment For Heart Disease

2024-08-22T12:58:06.000Z - 1 year ago

Cardiol Therapeutics: First-Mover In CBD-Based Treatment For Heart Disease

Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders

Thu, 27 Jun 2024 12:29:00 -0400 - 1 year ago

Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders

Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT

Tue, 25 Jun 2024 07:27:00 -0400 - 1 year ago

Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT

Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Thu, 13 Jun 2024 07:58:00 -0400 - 1 year ago

Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024

Tue, 14 May 2024 07:27:00 -0400 - 1 year ago

Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024

Cardiol Therapeutics Announces Year-End 2023 Update on Operations

Tue, 02 Apr 2024 06:00:00 -0400 - 2 years ago

Cardiol Therapeutics Announces Year-End 2023 Update on Operations

Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Wed, 21 Feb 2024 07:27:00 -0500 - 2 years ago

Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis

Thu, 15 Feb 2024 07:27:00 -0500 - 2 years ago

Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis

Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market

Wed, 24 Jan 2024 07:27:00 -0500 - 2 years ago

Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market

Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis

Jan 9, 2024, 7:27 AM EST - 2 years ago

Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis

Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot

Dec 5, 2023, 7:27 AM EST - 2 years ago

Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot

Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

Nov 16, 2023, 5:30 AM EST - 2 years ago

Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis

Nov 1, 2023, 7:27 AM EDT - 2 years ago

Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis

Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Oct 20, 2023, 5:00 PM EDT - 2 years ago

Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction

Oct 10, 2023, 6:00 AM EDT - 2 years ago

Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction

Cardiol Therapeutics to Present at Cantor Fitzgerald 2023 Global Healthcare Conference

Sep 26, 2023, 7:27 AM EDT - 2 years ago

Cardiol Therapeutics to Present at Cantor Fitzgerald 2023 Global Healthcare Conference

Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute Myocarditis

Sep 19, 2023, 7:27 AM EDT - 2 years ago

Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute Myocarditis

Cardiol Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference

Aug 9, 2023, 7:27 AM EDT - 2 years ago

Cardiol Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference

Covode13
Covode13 Mar. 12 at 12:49 PM
$CRDL
0 · Reply
TheWinningStock
TheWinningStock Mar. 11 at 9:41 PM
$CRDL ....🤑
1 · Reply
ElieoG
ElieoG Mar. 11 at 2:28 PM
$CRDL good volume allready and breaking some 3 months resistance, possible breakout?
1 · Reply
VixTyler
VixTyler Mar. 11 at 5:59 AM
$CRDL Completion of enrollment is expected by the end of Q2 2026, setting the stage for a top-line data readout in the second half of 2026.
0 · Reply
zeke1019
zeke1019 Mar. 10 at 3:30 PM
$CRDL insiders are buying... Cardiol Therapeutics (CRDL) has experienced significant, consistent insider buying, primarily in late 2024 and October 2025, with no recorded sales in the last 3 years. Key executives, including CEO David Elsley and CFO Christopher Waddick, bought shares, signaling confidence following positive Phase 2 trial results.
1 · Reply
Covode13
Covode13 Mar. 10 at 12:08 PM
$CRDL
0 · Reply
Fastcapital
Fastcapital Mar. 9 at 5:06 PM
$CRDL https://finance.yahoo.com/news/cardiol-therapeutics-touts-phase-iii-230226821.html
0 · Reply
zeke1019
zeke1019 Mar. 9 at 1:55 PM
$CRDL Steve Grasso /cnbc backing!
5 · Reply
Covode13
Covode13 Mar. 6 at 7:29 PM
$CRDL
0 · Reply
NancyPelosi____insider
NancyPelosi____insider Mar. 6 at 6:08 PM
$CRDL absolute dogshit
1 · Reply
RobbyAxelrod1
RobbyAxelrod1 Mar. 6 at 5:42 PM
$CRDL I'm out I thought they had more cash.
0 · Reply
ElieoG
ElieoG Mar. 6 at 2:10 AM
$CRDL for better or worse: Cardiol Therapeutics (CRDL) presented at the TD Cowen Health Care Conference on March 4, 2026, highlighting progress in its Phase III MAVERIC trial for recurrent pericarditis and recent positive data from its Phase II ARCHER study in acute myocarditis. Key updates included structural heart improvements in patients with acute myocarditis and a continued focus on its pipeline, The Globe and Mail reports. Phase II ARCHER Trial: Confirmed that CardiolRx™ significantly reduces inflammation-driven structural damage, including a reduction in left ventricular (LV) mass in patients with acute myocarditis. Phase III MAVERIC Trial: Continued progress on the trial for recurrent pericarditis. CRD-38 Development: Continued development for inflammatory heart disease. Financial Outlook: The company is managing a high cash burn rate, which presents financing and dilution risks despite positive clinical progress. The presentation aimed to increase visibility
1 · Reply
NancyPelosi____insider
NancyPelosi____insider Mar. 5 at 6:39 PM
$CRDL @Fastcapital when is something good going to happen?
2 · Reply
ElieoG
ElieoG Mar. 5 at 5:58 PM
$CRDL from bad to worse to even worse. I really thought 2026 was gonna be the year of bounce back. I need some Fast Capital bullishness right now.
1 · Reply
Covode13
Covode13 Mar. 4 at 10:14 PM
$CRDL
0 · Reply
Rbyild
Rbyild Mar. 4 at 9:03 PM
$CRDL Less than 92k shares traded. Why bother? Sorry for those that have held this high risk - frozen asset in their portfolio for the last 4-5 years. FYI…presenting at the Health Care Conferences does nothing. Please stick to making those 20k videos. 😂
1 · Reply
ElieoG
ElieoG Mar. 3 at 6:36 PM
$CRDL another 0 impact conference?
3 · Reply
PDM21
PDM21 Mar. 2 at 6:46 PM
$CRDL I’m actually a little impressed how stable this has been with in .15 or so for months now. Not proud of how low it is but seems to have decent support right here.
1 · Reply
TheWinningStock
TheWinningStock Feb. 28 at 7:07 PM
$CRDL $VXRT <<--- promising just like IBRX...
0 · Reply
RobbyAxelrod1
RobbyAxelrod1 Feb. 27 at 5:17 PM
$CRDL Poised for a move Up
0 · Reply
HeyYio
HeyYio Feb. 27 at 10:21 AM
$CRDL oh no no no ! Lets not do our thing. Our thing is to advance our trials and let our stock lanquish. Lets do something else !!
1 · Reply
Covode13
Covode13 Feb. 25 at 10:55 PM
$CRDL I have a lot of shares in my broker account. Was thinking of putting a few hundred in my Roth. Good idea?
1 · Reply